Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity. - Wikidata - awgldk - TriplyDB

Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

http://www.wikidata.org/entity/Q35567088

about

Management of bleeding and coagulopathy following major trauma: an updated European guideline.Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients Early and individualized goal-directed therapy for trauma-induced coagulopathy Point of care and factor concentrate-based coagulation algorithms The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.The role of prothrombin complex concentrates in reversal of target specific anticoagulants.Management of anticoagulant-related intracranial hemorrhage: an evidence-based review.Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery.Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network Group Prothrombin complex concentrate for warfarin-induced bleeding in a patient with a mechanical aortic valve.Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials Clinical use and the Italian demand for prothrombin complex concentrates Rivaroxaban and hemostasis in emergency care.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.Prothrombin complex concentrates in emergency bleeding disorders.Current state of knowledge on oral anticoagulant reversal using procoagulant factors.Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.Coagulation management with factor concentrates in liver transplantation: a single-center experience.Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate.Outcome measures and quality markers for perioperative blood loss and transfusion in cardiac surgery.Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.The epidemic of pre-injury oral antiplatelet and anticoagulant use.Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting.Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.Preparation of factor VII concentrate using CNBr-activated Sepharose 4B immunoaffinity chromatography.Thromboprophylaxis and Outcomes for Total Joint Arthroplasty in Congenital Bleeding Disorders: A Single-Center Experience.Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report.An acquired, calcium-dependent, factor X inhibitor.Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies.Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.Correction: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity.

P2860

Q21092902-9B7A7A7E-A114-41B4-A594-B2D9B72CF21F Q24186523-36DFA12C-9F08-4A13-95C8-A96C8BEFC2D9 Q26853422-BB65F681-4D17-4632-88B6-5B56491524F3 Q27010188-0774EADF-6125-446B-B50D-94D27BF7E18B Q27339343-224ADD85-714B-4C12-8DF0-A260A365C963 Q33430766-FC1F2072-F278-4E04-A92F-86C77C143EC6 Q33582537-94407C1E-3731-4D27-8BDC-B234866ABCEA Q33750215-F10C377D-21AA-4F39-80D6-74B60E053F58 Q34019616-7FC1591F-8650-42D1-AA82-D822E33F5735 Q34485905-4BB61DD4-441C-4F84-A870-76E3A2A072EE Q34654443-767E4668-1154-4118-A636-D6249128C6FE Q34734058-9B1D2904-2B14-4B9A-804D-20D9900099FB Q36175492-58B7033E-37D4-419B-8F90-4B39FD4FB2D0 Q36433257-1FE8ECA0-7DD5-4980-94B7-57ECFC91D2A1 Q36543599-28703BA0-DDC2-4481-BC7F-B9E825A12832 Q37024233-0EBE3C2E-6AEA-4723-B99E-469B69CD7491 Q37352419-F33D1115-4AE4-4A80-B382-65668EEEF2A9 Q37370338-24B6480A-C88B-4075-9D69-7A92A9332CF2 Q37631564-FF798557-24FF-497A-B6DB-4B53D8F86746 Q37927122-2C3370B2-29C7-479C-A81A-1BF8BDF101F3 Q38014751-C2C1AA37-345D-4524-BD95-BCE5C18A4B09 Q38108527-DCAE34EE-7731-43A4-9873-EC77976A4053 Q38197728-85B86BAC-E311-4E1F-851A-F72A24BCE632 Q38211682-85FFEF11-8A45-44B4-B48B-AECC4AECD443 Q38600324-424C8453-6359-4D8B-AB3D-F8F5E23DA68B Q38614138-0F4ACD36-25F4-4150-8939-9B7878B4F640 Q38720645-2CA6B0B2-D4BD-4C0D-8EE9-2626520631C1 Q38915687-5A8A3EF2-F473-4044-B7A4-15F0010A1DFB Q38928171-2551674B-24F2-4184-BAA2-F519D4CB226E Q40295049-AF61E257-FBB5-4788-8228-5A2F3992B87A Q40338659-0CDDAB9C-3D4C-4074-8609-19C8241A8EE9 Q40652331-AB192937-509B-47C1-AC16-0733E7507A30 Q40705500-E3A80E9E-EFE6-4124-80AE-10DD20F22200 Q40972656-09F984DF-2877-4691-8761-6AFD379403A3 Q42007287-3952D582-7E2F-499E-9F28-E44B5B22C1CA Q42103158-A6C1C5A3-FAA8-433D-B343-3D536069FBB9 Q42316665-503D2B57-2FDC-4914-8015-D8906D8EE8B0 Q45869388-0EC044F2-51D0-4599-A75C-8BF40F14FCB9 Q45874429-CBFFD6E1-4D84-4EE9-9541-588BDC46DC1B Q45900768-1F112C46-8938-4CF4-98CD-35FB050B3F95

P2860

Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

http://www.wikidata.org/entity/Q35567088

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@ast

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@en

type

label

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@ast

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@en

prefLabel

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@ast

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@en

P1433

Q35567088-D561D475-2818-4100-959D-1DA7B3246606

P1476

Q35567088-EA74946C-6688-4C3C-AACD-F47DFC2F0200

P2093

Q35567088-0BF29336-5772-4353-945F-2ADB70731E56

Q35567088-797E6FC6-6916-4BC2-ABD1-54376C2D5F5A

Q35567088-8A314CEC-93A0-43FA-A002-CD88E2DE6900

Q35567088-D663E1EE-B059-4F4B-B91E-60CBBF3805A3

Q35567088-ED699DE3-3402-4037-A624-0923435BAF53

P2860

Q35567088-02C27111-3584-47AB-A4DB-171FA9DE1619

Q35567088-0BC93D80-E3C1-4726-A1C7-1D7F0D7FAC6A

Q35567088-1826DEDC-F85C-46EB-A6AB-C59EF765E2E7

Q35567088-21CAB8FF-EC2A-48B2-B818-D4FC15F5AF9D

Q35567088-29F74C73-9A82-4A33-B1AE-D3D0D9F52873

Q35567088-2B043B8A-6DC8-4A23-8791-71F100511223

Q35567088-2CFFF08E-87FF-4578-A4CA-135593741D33

Q35567088-2D7BB0E6-3C31-4DBF-AC1E-F9BF993E949E

Q35567088-2E9DB691-291D-478A-A053-30C8C3237F89

Q35567088-2F346D02-9819-48D8-A9BD-7153D27D5C73

P2888

Q35567088-DE8A73E8-89D5-482E-B502-0324D0EF76E3

P304

Q35567088-C008DFBF-DF61-490A-B556-BCB791787A72

P31

Q35567088-538443D3-8BDA-4A88-8593-1B4574EC7A3D

Q35567088-7914B4F8-034E-48F7-B4B9-C909C7DBFAD8

P356

Q35567088-26F6E5C4-08D4-47C7-8679-6B7FEAF8C454

P433

Q35567088-23E67702-643B-417F-B892-B42AE0B15647

P478

Q35567088-5678CFE1-D85A-42E2-9DD4-F9FB681B70B9

P577

Q35567088-ADC3DD16-5134-482F-B4D4-5AEF30AFDDD6

P5875

Q35567088-16FF66A2-BC99-4EDC-A59E-A44343F99CA3

P6179

Q35567088-32DCE591-C32C-4F12-9191-FC9064B4584B

P698

Q35567088-B02BADF0-C9E3-493D-A2DE-12E0C9796383

P921

Q35567088-8E797443-1DB6-4FBD-B991-985FAEDED27A

P932

Q35567088-E0988C24-A0D8-4DC6-BFDE-17E20616A67F

P356

P1433

P1476

Clinical review: Prothrombin c ...... of safety and thrombogenicity.

@en

P2093

Benny Sørensen

http://www.w3.org/2001/XMLSchema#string

Donat R Spahn

http://www.w3.org/2001/XMLSchema#string

Michael Spannagl

http://www.w3.org/2001/XMLSchema#string

Petra Innerhofer

http://www.w3.org/2001/XMLSchema#string

Rolf Rossaint

http://www.w3.org/2001/XMLSchema#string

P2860

Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital

Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials.

Thrombin generation in patients with cirrhosis: the role of platelets.

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding

Thrombogenicity of prothrombin complex concentrates.

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

The hazards of blood transfusion in historical perspective.

The management of coumarin-induced over-anticoagulation Annotation.

Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography

Guidelines on oral anticoagulation (warfarin): third edition--2005 update.

P2888

P304

201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC9311

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49942667

http://www.w3.org/2001/XMLSchema#string

P6179

1051653308

http://www.w3.org/2001/XMLSchema#string

P698

21345266

http://www.w3.org/2001/XMLSchema#string

P921

P932

3222012

http://www.w3.org/2001/XMLSchema#string